دورية أكاديمية
ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors
| العنوان: | ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors |
|---|---|
| المؤلفون: | Evangelista L., Bianchi A., Annovazzi A., Sciuto R., Di Traglia S., Bauckneht M., Lanfranchi F., Morbelli S., Nappi A. G., Ferrari C., Rubini G., Panareo S., Urso L., Bartolomei M., D'Arienzo D., Valente T., Rossetti V., Caroli P., Matteucci F., Arico D., Bombaci M., Caponnetto D., Bertagna F., Albano D., Dondi F., Gusella S., Spimpolo A., Carriere C., Balma M., Buschiazzo A., Gallicchio R., Storto G., Ruffini L., Cervati V., Ledda R. E., Cervino A. R., Cuppari L., Burei M., Trifiro G., Brugola E., Zanini C. A., Alessi A., Fuoco V., Seregni E., Deandreis D., Liberini V., Moreci A. M., Ialuna S., Pulizzi S., De Rimini M. L. |
| المساهمون: | Evangelista, L., Bianchi, A., Annovazzi, A., Sciuto, R., Di Traglia, S., Bauckneht, M., Lanfranchi, F., Morbelli, S., Nappi, A. G., Ferrari, C., Rubini, G., Panareo, S., Urso, L., Bartolomei, M., D'Arienzo, D., Valente, T., Rossetti, V., Caroli, P., Matteucci, F., Arico, D., Bombaci, M., Caponnetto, D., Bertagna, F., Albano, D., Dondi, F., Gusella, S., Spimpolo, A., Carriere, C., Balma, M., Buschiazzo, A., Gallicchio, R., Storto, G., Ruffini, L., Cervati, V., Ledda, R. E., Cervino, A. R., Cuppari, L., Burei, M., Trifiro, G., Brugola, E., Zanini, C. A., Alessi, A., Fuoco, V., Seregni, E., Deandreis, D., Liberini, V., Moreci, A. M., Ialuna, S., Pulizzi, S., De Rimini, M. L. |
| سنة النشر: | 2023 |
| المجموعة: | Università degli Studi di Ferrara: CINECA IRIS |
| مصطلحات موضوعية: | 18F-FDG, immune-related effect, immunotherapy, PET/CT, therapy response |
| الوصف: | Simple Summary To examine the role of [18F]FDG PET/CT for assessing response to immunotherapy in patients with some solid tumors. Seventeen Italian centers analyzed the role of serial [18F]FDG PET/CT scans in patients candidates and, later undergoing immunotherapy for some solid cancers. Serial [18F]FDG PET/CT can be useful in evaluating the response to therapy, soon after 3 and 6-months from the start of immunotherapy. The evidences were foud both in patients affected by lung cancer and malignant melanoma, although large prospective trials are needed for definitively confirmed these findings. AIM: To examine the role of [18F]FDG PET/CT for assessing response to immunotherapy in patients with some solid tumors. METHODS: Data recorded in a multicenter (n = 17), retrospective database between March and November 2021 were analyzed. The sample included patients with a confirmed diagnosis of a solid tumor who underwent serial [18F]FDG PET/CT (before and after one or more cycles of immunotherapy), who were >18 years of age, and had a follow-up of at least 12 months after their first PET/CT scan. Patients enrolled in clinical trials or without a confirmed diagnosis of cancer were excluded. The authors classified cases as having a complete or partial metabolic response to immunotherapy, or stable or progressive metabolic disease, based on a visual and semiquantitative analysis according to the EORTC criteria. Clinical response to immunotherapy was assessed at much the same time points as the serial PET scans, and both the obtained responses were compared. RESULTS: The study concerned 311 patients (median age: 67; range: 31-89 years) in all. The most common neoplasm was lung cancer (56.9%), followed by malignant melanoma (32.5%). Nivolumab was administered in 46.3%, and pembrolizumab in 40.5% of patients. Baseline PET and a first PET scan performed at a median 3 months after starting immunotherapy were available for all 311 patients, while subsequent PET scans were obtained after a median 6, 12, 16, and 21 months for ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36765835; info:eu-repo/semantics/altIdentifier/wos/WOS:000929230800001; volume:15; issue:3; firstpage:878-1; lastpage:878-16; numberofpages:16; journal:CANCERS; https://hdl.handle.net/11392/2509473Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85147820424; https://www.mdpi.com/2072-6694/15/3/878Test |
| DOI: | 10.3390/cancers15030878 |
| الإتاحة: | https://doi.org/10.3390/cancers15030878Test https://hdl.handle.net/11392/2509473Test https://www.mdpi.com/2072-6694/15/3/878Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.4189A4B7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/cancers15030878 |
|---|